Literature DB >> 29237704

TESTING Corticosteroids in IgA Nephropathy: A Continuing Challenge.

Frederick W K Tam1, Charles D Pusey2.   

Abstract

Entities:  

Keywords:  Adrenal Cortex Hormones; Biopsy; Chronic; Glomerulonephritis; Hematuria; Humans; IGA; IgA nephropathy; Immunoglobulin A; Kidney Failure; Prevalence; Prognosis; adverse events; corticosteroids; glomerulonephritis; hypertension; kidney; kidney function; proteinuria

Mesh：

Substances：

Year:  2017        PMID： 29237704      PMCID： PMC5753322          DOI： 10.2215/CJN.10560917

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

1.  Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.

Authors:  Jin-Hua Hou; Wei-Bo Le; Nan Chen; Wei-Ming Wang; Zhang-Suo Liu; Dong Liu; Jiang-Hua Chen; Jiong Tian; Ping Fu; Zhang-Xue Hu; Cai-Hong Zeng; Shao-Shan Liang; Min-Lin Zhou; Hai-Tao Zhang; Zhi-Hong Liu
Journal:  Am J Kidney Dis       Date:  2017-02-16       Impact factor: 8.860

2.  The MEST score provides earlier risk prediction in lgA nephropathy.

Authors:  Sean J Barbour; Gabriela Espino-Hernandez; Heather N Reich; Rosanna Coppo; Ian S D Roberts; John Feehally; Andrew M Herzenberg; Daniel C Cattran
Journal:  Kidney Int       Date:  2016-01       Impact factor: 10.612

3.  A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Authors:  Richard A Lafayette; Pietro A Canetta; Brad H Rovin; Gerald B Appel; Jan Novak; Karl A Nath; Sanjeev Sethi; James A Tumlin; Kshama Mehta; Marie Hogan; Stephen Erickson; Bruce A Julian; Nelson Leung; Felicity T Enders; Rhubell Brown; Barbora Knoppova; Stacy Hall; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 10.121

4.  Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Authors:  Bengt C Fellström; Jonathan Barratt; Heather Cook; Rosanna Coppo; John Feehally; Johan W de Fijter; Jürgen Floege; Gerd Hetzel; Alan G Jardine; Francesco Locatelli; Bart D Maes; Alex Mercer; Fernanda Ortiz; Manuel Praga; Søren S Sørensen; Vladimir Tesar; Lucia Del Vecchio
Journal:  Lancet       Date:  2017-03-28       Impact factor: 79.321

5.  Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes.

Authors:  Penelope J Allen; Steve J Chadban; Jonathan C Craig; Wai H Lim; Richard D M Allen; Philip A Clayton; Armando Teixeira-Pinto; Germaine Wong
Journal:  Kidney Int       Date:  2017-08       Impact factor: 10.612

6.  Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.

Authors:  Vladimir Tesar; Stéphan Troyanov; Shubha Bellur; Jacobien C Verhave; H Terence Cook; John Feehally; Ian S D Roberts; Daniel Cattran; Rosanna Coppo
Journal:  J Am Soc Nephrol       Date:  2015-02-12       Impact factor: 10.121

7.  Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy.

Authors:  Cristina Sarcina; Carmine Tinelli; Francesca Ferrario; Antonello Pani; Annalisa De Silvestri; Patrizia Scaini; Lucia Del Vecchio; Elena Alberghini; Laura Buzzi; Ivano Baragetti; Claudio Pozzi
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-29       Impact factor: 8.237

8.  Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Authors:  Thomas Rauen; Frank Eitner; Christina Fitzner; Claudia Sommerer; Martin Zeier; Britta Otte; Ulf Panzer; Harm Peters; Urs Benck; Peter R Mertens; Uwe Kuhlmann; Oliver Witzke; Oliver Gross; Volker Vielhauer; Johannes F E Mann; Ralf-Dieter Hilgers; Jürgen Floege
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245

9.  Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

Authors:  Jicheng Lv; Hong Zhang; Muh Geot Wong; Meg J Jardine; Michelle Hladunewich; Vivek Jha; Helen Monaghan; Minghui Zhao; Sean Barbour; Heather Reich; Daniel Cattran; Richard Glassock; Adeera Levin; David Wheeler; Mark Woodward; Laurent Billot; Tak Mao Chan; Zhi-Hong Liu; David W Johnson; Alan Cass; John Feehally; Jürgen Floege; Giuseppe Remuzzi; Yangfeng Wu; Rajiv Agarwal; Hai-Yan Wang; Vlado Perkovic
Journal:  JAMA       Date:  2017-08-01       Impact factor: 56.272

10.  Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy.

Authors:  Yong-Chul Kim; Ho Jun Chin; Ho Suk Koo; Suhnggwon Kim
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240
  10 in total
  4 in total

1.  Efficacy and safety of glucocorticoids for patients with IgA nephropathy: a meta-analysis.

Authors:  Ge Qian; Xiaoyu Zhang; Weicheng Xu; Hequn Zou; Yongqiang Li
Journal:  Int Urol Nephrol       Date:  2019-03-06       Impact factor: 2.370

Review 2.  Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Yu Zhao; Heng Fan; Bei-Yan Bao
Journal:  Iran J Public Health       Date:  2019-09       Impact factor: 1.429

3.  Glomerular C4d Deposition and Kidney Disease Progression in IgA Nephropathy: A Systematic Review and Meta-analysis.

Authors:  Yuanyuan Jiang; Jincan Zan; Sufang Shi; Wanyin Hou; Wenjing Zhao; Xuhui Zhong; Xujie Zhou; Jicheng Lv; Hong Zhang
Journal:  Kidney Med       Date:  2021-08-06

4.  Lipidomics reveals association of circulating lipids with body mass index and outcomes in IgA nephropathy patients.

Authors:  Yueyi Deng; Qingqing Wu; Wanjia Chen; Li Zhu; Wangyi Liu; Fangying Xia; Liang Sun; Xu Lin; Rong Zeng
Journal:  J Mol Cell Biol       Date:  2021-07-17       Impact factor: 6.216
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.